Literature DB >> 18571483

Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.

Marc De Meulder1, Bart M M Remmerie, Ronald de Vries, Luc L A Sips, Sandra Boom, Edwin W J Hooijschuur, Nico C van de Merbel, Philip M M B L Timmerman.   

Abstract

Two liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods are described, one for the quantitative determination of risperidone and the enantiomers of its active metabolite 9-hydroxyrisperidone (paliperidone) in human plasma and the other for the determination of the enantiomers of 9-hydroxyrisperidone in human urine. The plasma method is based on solid-phase extraction of 200 microl of sample on a mixed-mode sorbent, followed by separation on a cellulose-based LC column with a 13.5-min mobile phase gradient of hexane, isopropanol and ethanol. After post-column addition of 10 mM ammonium acetate in ethanol/water, detection takes place by ion-spray tandem mass spectrometry in the positive ion mode. Method validation results show that the method is sufficiently selective towards the enantiomers of 7-hydroxyrisperidone and capable of quantifying the analytes with good precision and accuracy in the concentration range of 0.2-100 ng/ml. An accelerated (run time of 4.3 min) and equally valid method for the enantiomers of 9-hydroxyrisperidone alone in plasma is obtained by increasing the mobile phase flow-rate from 1.0 to 2.0 ml/min and slightly adapting the gradient conditions. The urine method is based on the same solid-phase extraction and chromatographic approach as the accelerated plasma method. Using 100 microl of sample, (+)- and (-)-9-hydroxyrisperidone can be quantified in the concentration range 1-2000 ng/ml. The accelerated method for plasma and the method for urine can be used only when paliperidone is administered instead of risperidone, as there is insufficient separation of the 9-hydroxy enantiomers from the 7-hydroxy enantiomers, the latter ones being present only after risperidone administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571483     DOI: 10.1016/j.jchromb.2008.04.041

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.

Authors:  Mats O Magnusson; Mahesh N Samtani; Elodie L Plan; E Niclas Jonsson; Stefaan Rossenu; An Vermeulen; Alberto Russu
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

2.  Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.

Authors:  Natchaya Vanwong; Santirat Prommas; Apichaya Puangpetch; Yaowaluck Hongkaew; Nopadol Nuntamool; Chalitpol Na Nakorn; Nattawat Ngamsamut; Penkhae Limsila; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2016-06-26       Impact factor: 2.352

3.  Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.

Authors:  Mahesh N Samtani; An Vermeulen; Kim Stuyckens
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Stability indicating HPLC determination of risperidone in bulk drug and pharmaceutical formulations.

Authors:  Zarna R Dedania; Ronak R Dedania; Navin R Sheth; Jigar B Patel; Bhavna Patel
Journal:  Int J Anal Chem       Date:  2011-10-10       Impact factor: 1.885

5.  UPLC-Tandem Mass Spectrometry Method for Simultaneous Determination of Fluoxetine, Risperidone, and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Pharmacokinetics Study in Rats.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam
Journal:  J Anal Methods Chem       Date:  2017-06-01       Impact factor: 2.193

6.  Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia.

Authors:  Hiroko Shimizu; Martine Neyens; Marc De Meulder; Srihari Gopal; Yuko Tsukamoto; Mahesh N Samtani; Bart Remmerie
Journal:  Clin Pharmacol Drug Dev       Date:  2019-12-25

7.  A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.

Authors:  Praveen Srivastava; Ganesh S Moorthy; Robert Gross; Jeffrey S Barrett
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

8.  Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose.

Authors:  Mahesh N Samtani; Isaac Nuamah; Srihari Gopal; Bart Remmerie; Jennifer Kern Sliwa; Larry Alphs
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-20       Impact factor: 2.570

9.  Use of the Charge Transfer Reactions for the Spectrophotometric Determination of Risperidone in Pure and in Dosage Forms.

Authors:  Hemavathi Nagaraju Deepakumari; Hosakere Doddarevanna Revanasiddappa
Journal:  J Pharm (Cairo)       Date:  2012-11-26

10.  Sensitive method for the quantitative determination of risperidone in tablet dosage form by high-performance liquid chromatography using chlordiazepoxide as internal standard.

Authors:  Safwan Ashour; Nuha Kattan
Journal:  Int J Biomed Sci       Date:  2013-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.